About
Technology
Issues
FAQ
Search
Scientometrics
Impact Factor
Discipline Ranks
h
-index
g
-index
Articles
Citations
Article Citations
Citation Distribution
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Journals
›
Molecular Therapy - Methods and Clinical Development
›
top-articles
Molecular Therapy - Methods and Clinical Development
4.4
(top 10%)
impact factor
1.2K
(top 20%)
papers
24.0K
(top 10%)
citations
61
(top 10%)
h
-index
4.5
(top 10%)
impact factor
1.5K
all documents
27.4K
doc citations
92
(top 10%)
g
-index
Top Articles
#
Title
Journal
Year
Citations
1
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Molecular Therapy - Methods and Clinical Development
2018
578
2
Global Manufacturing of CAR T Cell Therapy
Molecular Therapy - Methods and Clinical Development
2017
480
3
Engineering and Design of Chimeric Antigen Receptors
Molecular Therapy - Methods and Clinical Development
2019
281
4
Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD
Molecular Therapy - Methods and Clinical Development
2020
231
5
Production and clinical development of nanoparticles for gene delivery
Molecular Therapy - Methods and Clinical Development
2016
207
6
Manufacturing of recombinant adeno-associated viral vectors for clinical trials
Molecular Therapy - Methods and Clinical Development
2016
198
7
Production of lentiviral vectors
Molecular Therapy - Methods and Clinical Development
2016
192
8
Clinical development of gene therapy: results and lessons from recent successes
Molecular Therapy - Methods and Clinical Development
2016
183
9
Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
Molecular Therapy - Methods and Clinical Development
2018
181
10
Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors
Molecular Therapy - Methods and Clinical Development
2019
168
11
Oncolytic Viruses and the Immune System: The Dynamic Duo
Molecular Therapy - Methods and Clinical Development
2020
152
12
Improved Loading of Plasma-Derived Extracellular Vesicles to Encapsulate Antitumor miRNAs
Molecular Therapy - Methods and Clinical Development
2019
151
13
Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing in Bone-Marrow-Derived CD34 + Hematopoietic Stem and Progenitor Cells
Molecular Therapy - Methods and Clinical Development
2017
131
14
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Molecular Therapy - Methods and Clinical Development
2018
125
15
Pharmacology of Recombinant Adeno-associated Virus Production
Molecular Therapy - Methods and Clinical Development
2018
124
16
Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine
Molecular Therapy - Methods and Clinical Development
2018
116
17
Barriers and Strategies of Cationic Liposomes for Cancer Gene Therapy
Molecular Therapy - Methods and Clinical Development
2020
115
18
The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19
Molecular Therapy - Methods and Clinical Development
2020
114
19
Mesenchymal Stem Cells Overexpressing Interleukin-10 Promote Neuroprotection in Experimental Acute Ischemic Stroke
Molecular Therapy - Methods and Clinical Development
2017
110
20
Gene Transfer with AAV9-PHP.B Rescues Hearing in a Mouse Model of Usher Syndrome 3A and Transduces Hair Cells in a Non-human Primate
Molecular Therapy - Methods and Clinical Development
2019
110
21
Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing
Molecular Therapy - Methods and Clinical Development
2017
106
22
EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
Molecular Therapy - Methods and Clinical Development
2019
106
23
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Molecular Therapy - Methods and Clinical Development
2014
101
24
Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors
Molecular Therapy - Methods and Clinical Development
2019
100
25
Engineering Nanoparticles for Targeted Delivery of Nucleic Acid Therapeutics in Tumor
Molecular Therapy - Methods and Clinical Development
2019
100
26
A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials
Molecular Therapy - Methods and Clinical Development
2018
96
27
Thermal Stability as a Determinant of AAV Serotype Identity
Molecular Therapy - Methods and Clinical Development
2017
95
28
An Introduction to the Analysis of Single-Cell RNA-Sequencing Data
Molecular Therapy - Methods and Clinical Development
2018
95
29
A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing
Molecular Therapy - Methods and Clinical Development
2019
93
30
Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects
Molecular Therapy - Methods and Clinical Development
2014
92
31
Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem/progenitor cells
Molecular Therapy - Methods and Clinical Development
2016
91
32
Microglia-specific targeting by novel capsid-modified AAV6 vectors
Molecular Therapy - Methods and Clinical Development
2016
91
33
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs
Molecular Therapy - Methods and Clinical Development
2019
89
34
Selection of an Efficient AAV Vector for Robust CNS Transgene Expression
Molecular Therapy - Methods and Clinical Development
2019
89
35
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Molecular Therapy - Methods and Clinical Development
2020
89
36
Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes
Molecular Therapy - Methods and Clinical Development
2018
88
37
Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma
Molecular Therapy - Methods and Clinical Development
2018
87
38
Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy
Molecular Therapy - Methods and Clinical Development
2018
85
39
Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies
Molecular Therapy - Methods and Clinical Development
2021
85
40
Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna
Molecular Therapy - Methods and Clinical Development
2014
84
41
Adeno-associated viral vectors do not efficiently target muscle satellite cells
Molecular Therapy - Methods and Clinical Development
2014
84
42
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses
Molecular Therapy - Methods and Clinical Development
2016
83
43
Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia Major
Molecular Therapy - Methods and Clinical Development
2018
83
44
INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes
Molecular Therapy - Methods and Clinical Development
2017
81
45
Methods Matter: Standard Production Platforms for Recombinant AAV Produce Chemically and Functionally Distinct Vectors
Molecular Therapy - Methods and Clinical Development
2020
80
46
Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques
Molecular Therapy - Methods and Clinical Development
2018
79
47
A Five-Repeat Micro-Dystrophin Gene Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of Duchenne Muscular Dystrophy
Molecular Therapy - Methods and Clinical Development
2017
78
48
The Pharmacology of T Cell Therapies
Molecular Therapy - Methods and Clinical Development
2018
78
49
Expression of Human ACE2 in Lactobacillus and Beneficial Effects in Diabetic Retinopathy in Mice
Molecular Therapy - Methods and Clinical Development
2019
78
50
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
Molecular Therapy - Methods and Clinical Development
2019
77
site/software ©
exaly
; All materials licenced under
CC by-SA
.